CA9 and cancer: Treatment with 100 μM of SLC-0111 for 72 h affects the viability of the high-malignant acid cancer subpopulation particularly addicted to CAIX activity, i.e., the cells growing under specific conditions of acidosis within the tumor mass of the breast, melanoma and colorectal tumors.